- Home
- MRT vs MGNX Comparison
MRT vs MGNX Comparison
Compare MRT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- MGNX
- Stock Information
- Founded
- MRT 2018
- MGNX 2000
- Country
- MRT Turkey
- MGNX United States
- Employees
- MRT N/A
- MGNX N/A
- Industry
- MRT Rental/Leasing Companies
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MRT Consumer Discretionary
- MGNX Health Care
- Exchange
- MRT Nasdaq
- MGNX Nasdaq
- Market Cap
- MRT 181.8M
- MGNX 202.7M
- IPO Year
- MRT N/A
- MGNX 2013
- Fundamental
- Price
- MRT $3.45
- MGNX $2.76
- Analyst Decision
- MRT
- MGNX Hold
- Analyst Count
- MRT 0
- MGNX 10
- Target Price
- MRT N/A
- MGNX $7.17
- AVG Volume (30 Days)
- MRT 41.3K
- MGNX 768.5K
- Earning Date
- MRT 01-01-0001
- MGNX 03-06-2025
- Dividend Yield
- MRT N/A
- MGNX N/A
- EPS Growth
- MRT N/A
- MGNX N/A
- EPS
- MRT N/A
- MGNX N/A
- Revenue
- MRT $18,953,502.00
- MGNX $141,329,000.00
- Revenue This Year
- MRT N/A
- MGNX $174.73
- Revenue Next Year
- MRT $101.81
- MGNX N/A
- P/E Ratio
- MRT N/A
- MGNX N/A
- Revenue Growth
- MRT N/A
- MGNX 16.68
- 52 Week Low
- MRT $0.71
- MGNX $2.34
- 52 Week High
- MRT $3.89
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- MRT 55.09
- MGNX 45.32
- Support Level
- MRT $2.86
- MGNX $2.34
- Resistance Level
- MRT $3.70
- MGNX $2.95
- Average True Range (ATR)
- MRT 0.23
- MGNX 0.17
- MACD
- MRT 0.03
- MGNX 0.03
- Stochastic Oscillator
- MRT 70.36
- MGNX 61.76
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, operating a fleet of over 48,000 e-mopeds, e-bikes, and e-scooters, serviced by proprietary software systems and IoT infrastructure.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).